塞力斯医疗科技集团股份有限公司 重大交易决策制度 塞力斯医疗科技集团股份有限公司 重大交易决策制度 （2025 年 8 月） 第一条 为加强对塞力斯医疗科技集团股份有限公司（以下简称"公司"） 重大交易活动的决策管理，保证重大交易活动的规范性、合法性和效益性，切 实保护公司利益各方的合法权益，根据《中华人民共和国公司法》《中华人民 共和国证券法》《上海证券交易所股票上市规则》等相关法律、法规和《塞力 斯医疗科技集团股份有限公司章程》（以下简称"《公司章程》"）的规定， 制定本制度。 第二条 公司应当严格遵守有关法律、法规及《公司章程》的规定，在交 易决策中，保障股东会、董事会和董事长、经理（总裁）各自的权限得到有效 发挥，做到权责分明，保证公司运作效率。 第三条 本制度所称"重大交易"包括除公司日常经营活动之外发生的下 列事项： (一)购买或出售资产； (二)对外投资（含委托理财、对子公司投资等）； (三)提供财务资助（含有息或者无息借款、委托贷款等）； (四)提供担保（含对控股子公司担保等）； (十一)放弃权利（含放弃优先购买权、优先认缴出资权等）； (十二)证券交易所认定的其他交易。 塞力斯医疗科技集团股 ...

Core Points - The document outlines the major transaction decision-making system of Yantai Zhenghai Biological Technology Co., Ltd, ensuring compliance with relevant laws and regulations [1] - The system aims to clarify the responsibilities and powers of the shareholders' meeting, board of directors, and general manager to enhance operational efficiency [1] Chapter 1: General Principles - The company must adhere to the Company Law and the Shenzhen Stock Exchange's rules while making transaction decisions [1] - Transactions include asset purchases or sales, external investments, financial assistance, guarantees, leasing, management contracts, donations, debt restructuring, licensing agreements, R&D project transfers, and rights waivers [1] Chapter 2: Transaction Approval Authority - Transactions exceeding certain thresholds must be submitted to the board of directors for review, including those where the total asset amount exceeds 10% of the latest audited total assets or where the transaction amount exceeds 50 million yuan [2][3] - Transactions that meet specific criteria, such as involving assets over 50% of total audited assets or generating profits over 50% of the latest audited net profit, must be submitted to the shareholders' meeting for approval [4] - For equity transactions that change the scope of consolidated financial statements, the entire asset and revenue of the corresponding company must be considered [4] - The company must hire qualified accounting firms to audit financial reports for equity transactions and qualified asset appraisal firms for non-cash asset transactions [5] - If the total asset amount or transaction amount reaches 30% of the latest audited total assets within 12 months, it must be disclosed and submitted for shareholder approval [6] - Financial assistance transactions require approval from two-thirds of the board and may need to be submitted to the shareholders' meeting under certain conditions [6] Chapter 3: Miscellaneous - The decision-making standards outlined in the document must be followed unless conflicting with national laws and regulations [7] - The company’s shareholders, directors, and independent directors have the right to supervise and question the general manager's actions [8] - The document will be implemented upon approval by the shareholders' meeting and is subject to interpretation by the board of directors [8]